Tecadenoson

337.33100

337.33

GZ1X96601Z

DTXSID80174415

134.78000

-1.28840

1.89g/cm3

704.9ºC at 760 mmHg

380.1ºC

1.83

7.4E-21mmHg at 25°C

Investigated for use/treatment in arrhythmia and atrial fibrillation.

Tecadenoson is a novel A1 adenosine receptor stimulator. Adenosine is a naturally occurring compound that stimulates all adenosine receptor subtypes in the body, including the A2 adenosine receptor which lowers blood pressure. In non-clinical trials, tecadenoson selectively stimulated the A1 adenosine receptor in the AV node and slowed the speed of electrical conduction across the AV node, reducing the number of electrical impulses that reached the ventricle, without affecting blood pressure. Clinical studies to date with intravenous tecadenoson suggest that it may slow the speed of AV nodal conduction by selectively stimulating the A1 adenosine receptor, and may avoid blood pressure lowering by not stimulating the A2 adenosine receptor. Thus, it may be possible to use intravenous tecadenoson to convert patients from PSVT to normal sinus rhythm without lowering blood pressure or causing adverse events related to vasodilitation such as flushing, palpitations or headache.

Compounds that bind to and stimulate PURINERGIC P1 RECEPTORS. (See all compounds classified as Purinergic P1 Receptor Agonists.)

Tecadenoson selectively stimulates the A1 adenosine receptor. Stimulation of the A1 adenosine receptor slows the conduction of electrical impulses in the AV node of the heart, a region that controls the transmission of electrical impulses from the atria to the ventricles.

CVT 510